Elusys Therapeutics Recieves Funding to Develop Treatment for Inhalation Anthrax Infection

Pharmaceutical Investing

Elusys Therapeutics has received $16 million in additional funding from the U.S. Government to ​support its development of a treatment for inhalation anthrax infection. The company is developing a lyophilized form of Anthim® (obiltoxaximab).

Elusys Therapeutics has received $16 million in additional funding from the U.S. Government to ​support its development of a treatment for inhalation anthrax infection. The company is developing a lyophilized form of Anthim® (obiltoxaximab).
According to Pharmaceutical Processing:

The company has now received total authorized funding of $195 million under two advanced development contracts for Anthim from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
Lyophilization (freeze drying) of the current liquid formulation of Anthim has the potential to extend product shelf-life once in the Strategic National Stockpile (SNS), the U.S. Government’s repository of critical medical supplies for biowarfare and public health emergency preparedness. Lyophilization also has the potential toimprove tolerance of Anthim to extreme temperatures during shipping and field use. These improvements could enhance operational flexibility and improve life cycle management.

Click here to read the full article from Pharmaceutical Processing.


The Conversation (0)